Gene Activity in Colon Polyps of People With Fatty Liver Disease (MASH)
Studies gene activity in colon polyps of adults with MASH versus without fatty liver.
Plain-language title generated from the registry record
Registry title: High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-70 with fatty liver disease (MASH) who are already scheduled to have colon polyps removed. Researchers will study polyp tissue and blood.
- Age
- 18 Years to 70 Years
- Sex
- Men and women
- Disease stage
- Fatty liver disease (MAFLD/MASH) diagnosed by the 2018 Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease.
Main reasons for not taking part
- Chronic liver disease from other causes (alcohol, viral, autoimmune, drug-induced)
- Decompensated cirrhosis or primary liver cancer
- Disease of other vital organs (heart, kidney, lung) or bleeding disorders
- People who lack legal capacity or have poor insight
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07463287, who can take part
Where in China
- Shanghai East HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai East Hospital
- Trial code
- NCT07463287
- Record updated
- 11 March 2026
- Original description
The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and to identify potential transcriptomic biomarkers for high-risk polyps. The main questions it aims to answer are: What are the key gene expression differences in adenomatous polyps between MASH patients and non-fatty liver individuals? Can specific high-risk transcriptional molecules in plasma and polyp tissue serve as biomarkers for MASH-related colorectal polyps? Participants already scheduled for colonoscopic polypectomy as part of their routine care will provide a small portion of their polyp tissue, residual plasma from standard blood tests, and allow use of their stored pathological slides for research; they will also be followed up every six months.Read full original descriptionShow less
High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and to identify potential transcriptomic biomarkers for high-risk polyps. The main questions it aims to answer are: What are the key gene expression differences in adenomatous polyps between MASH patients and non-fatty liver individuals? Can specific high-risk transcriptional molecules in plasma and polyp tissue serve as biomarkers for MASH-related colorectal polyps? Participants already scheduled for colonoscopic polypectomy as part of their routine care will provide a small portion of their polyp tissue, residual plasma from standard blood tests, and allow use of their stored pathological slides for research; they will also be followed up every six months.
Inclusion: Diagnosis of MAFLD conforms to the "Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease" (2018 Edition); Male or female patients aged 18-70 years; Signed informed consent form and explanation of the specific study protocol.
Exclusion: Chronic liver disease due to other etiologies (alcoholic, viral, autoimmune, drug-induced, etc.), decompensated cirrhosis, primary liver cancer; Underlying diseases of other vital organs (heart, kidney, lung, etc.) and bleeding disorders; Individuals lacking legal capacity or with poor insight.